Home › Funds › Paradigm Biocapital Advisors LP › LXEO

Paradigm Biocapital Advisors LP position in LXEO

LEXEO THERAPEUTICS INC COM · Health Care

Paradigm Biocapital Advisors LP reported holding 4,175,382 shares of LXEO (LEXEO THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$19.4M, representing 0.36% of its reported portfolio and ranking #26 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed LXEO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)4.18M sh
Reported value held$19.44M
Portfolio Weight0.36%
First reportedQ4 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Paradigm Biocapital Advisors LP's LXEO position evolved

Paradigm Biocapital Advisors LP first disclosed a stake in LXEO in Q4 2025 at 4,763,198 shares (US$47.3M). Across 3 filings, Paradigm Biocapital Advisors LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 4,175,382 shares valued at US$19.4M — a reduction of -2,008,752 shares quarter over quarter.. Notable position changes include a 30% increase in Q1 2026 (shares fell 19% over the following quarter), a 32% trim in Q2 2026 (shares fell 27% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 4.76M $47.30M New
Q1 2026 6.18M $35.50M Add
Q2 2026 4.18M $19.44M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LXEO and 13F data

LXEO (LEXEO THERAPEUTICS INC COM) is a Health Care company. 40 other funds we track also report a position in LXEO — the largest reported positions include MONTANOVA CAPITAL, LLC (US$29.7M), Affinity Asset Advisors, LLC (US$27.0M), Frazier Life Sciences Management, L.P. (US$22.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LXEO

All LXEO fund holders →

FAQ

How long has Paradigm Biocapital Advisors LP held LXEO?

Paradigm Biocapital Advisors LP has disclosed LXEO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Paradigm Biocapital Advisors LP's current position in LXEO?

As of Q2 2026, Paradigm Biocapital Advisors LP holds 4.18M shares of LXEO (LEXEO THERAPEUTICS INC COM), valued at $19.44M, representing 0.36% of its reported portfolio and ranking #26.

Has Paradigm Biocapital Advisors LP been buying or selling LXEO?

In the latest 13F filing (Q2 2026), Paradigm Biocapital Advisors LP reduced its position in LXEO.

Which other funds hold LXEO?

Other major institutional holders of LXEO include MONTANOVA CAPITAL, LLC, Affinity Asset Advisors, LLC, Frazier Life Sciences Management, L.P., among 40 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.